Global Intermittent Flow Apheresis Devices Market Size By Type (Plasma Separators, Plasma Component Separators), By Application (Plasmapheresis, Plateletpheresis), By Region, And Segment Forecasts, 20...

The Global Intermittent Flow Apheresis Devices Market was valued at USD 1.1 billion in 2023 and is expected to surpass USD 2.3 billion by 2031, growing at a CAGR of 9.6% during the forecast period from 2023 to 2031. The market is witnessing robust growth owing to increasing demand for blood component separation, a rising number of therapeutic apheresis procedures, and growing awareness about advanced blood purification methods. Intermittent flow apheresis devices offer a cost-effective and flexible solution, making them suitable for both developed and emerging markets.

Drivers

Rising Prevalence of Chronic Diseases:

The increasing incidence of autoimmune diseases, hematological disorders, and kidney diseases is driving the adoption of therapeutic apheresis procedures. These conditions often require the removal or exchange of specific blood components, making intermittent flow apheresis devices essential in treatment protocols.

Growth in Blood Donation Activities:

Government initiatives and NGO campaigns promoting voluntary blood donation are increasing the availability of donor blood, leading to a higher demand for blood component separation technologies.

Technological Advancements in Apheresis Equipment:

Modern intermittent flow devices offer enhanced portability, automation, and patient comfort. Integration with real-time monitoring systems and improved safety features is encouraging wider adoption in hospitals and blood banks.

Restraints

High Cost of Advanced Devices:

Despite their efficiency, the high initial and maintenance costs of intermittent flow apheresis devices can limit adoption, particularly in cost-sensitive and underfunded healthcare systems.

Limited Awareness and Accessibility in Developing Regions:

In many emerging economies, a lack of awareness among healthcare professionals and patients, coupled with inadequate healthcare infrastructure, restricts the market penetration of apheresis technologies.

Opportunity

Expansion in Emerging Healthcare Markets:

Countries in Asia-Pacific, Latin America, and Africa are witnessing improvements in healthcare infrastructure and diagnostics. This trend presents significant growth opportunities for intermittent flow apheresis device manufacturers.

R&D in Precision Apheresis Treatments:

Growing investment in research related to personalized medicine and cell therapy is likely to boost the development of application-specific apheresis protocols, which can expand the market for intermittent flow systems.

Market by System Type Insights

The Plasma Exchange Devices segment dominated the market in 2023. These devices are widely used for treating autoimmune conditions like Guillain-Barré syndrome and myasthenia gravis. Their relatively simple setup and compatibility with intermittent flow configurations make them a preferred choice in various therapeutic settings. The Red Blood Cell Exchange Devices segment is expected to witness the highest CAGR during the forecast period, propelled by rising cases of sickle cell disease and malaria.

Market by End-use Insights

Hospitals & Clinics accounted for the largest market share in 2023, primarily due to the increasing number of apheresis procedures conducted for both therapeutic and donor-based applications. The Blood Banks & Transfusion Centers segment is projected to grow at a notable rate as global efforts to streamline and enhance blood collection and component separation intensify.

Market by Regional Insights

North America led the market in 2023, supported by a well-established healthcare system, high awareness, and the early adoption of apheresis technologies. Asia-Pacific is expected to exhibit the fastest growth, driven by rising healthcare expenditure, improving diagnostics, and a growing patient base in countries such as China and India.

Competitive Scenario

Prominent companies in the Global Intermittent Flow Apheresis Devices Market include Terumo BCT, Haemonetics Corporation, Fresenius Kabi, Asahi Kasei Medical, Kawasumi Laboratories, Nikkiso Co., Ltd., and Cerus Corporation. These players are actively engaged in technological innovation, strategic collaborations, and regional expansions to strengthen their global footprint.

Key Market Developments:

In 2023, Haemonetics Corporation launched a next-generation intermittent flow device with enhanced patient interface and digital connectivity.

In 2024, Terumo BCT announced a partnership with a leading hospital chain in India to supply mobile apheresis units for rural healthcare outreach programs.

In 2025, Fresenius Kabi received FDA approval for its new intermittent flow device optimized for pediatric care.

Scope of Work – Global Intermittent Flow Apheresis Devices Market

Report Metric Details

Market Size (2023)